arrow_back Back to App

Medical Innovation Act: Funding Research from Pharmaceutical Penalties

This act introduces a new funding mechanism for medical research. Pharmaceutical companies selling blockbuster drugs developed with partial federal investment, and that have previously settled legal violations, will pay supplemental fees. These funds will be directed towards urgent medical research needs, potentially accelerating the development of new treatments and therapies for citizens.
Key points
Supplemental payments from large pharmaceutical companies: Companies with billion-dollar sales from publicly-supported drugs and past legal settlements will pay special fees.
Support for medical research: Collected funds will go to the Food and Drug Administration (FDA) and National Institutes of Health (NIH) for research into difficult-to-treat diseases, new diagnostics and therapies, and support for early-career scientists.
Transparency and oversight: The government will publish information on companies subject to payments and how funds are used, ensuring accountability for research spending.
Failure to pay has consequences: Drugs from companies that do not remit required payments may be deemed unlawful, potentially affecting their market availability.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_9687
Sponsor: Rep. Welch, Peter [D-VT-At Large]
Process start date: 2022-12-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Medical Innovation Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_9687.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-12-22.

What are the main provisions?

Key points include:

  • Supplemental payments from large pharmaceutical companies: Companies with billion-dollar sales from publicly-supported drugs and past legal settlements will pay special fees.
  • Support for medical research: Collected funds will go to the Food and Drug Administration (FDA) and National Institutes of Health (NIH) for research into difficult-to-treat diseases, new diagnostics and therapies, and support for early-career scientists.
  • Transparency and oversight: The government will publish information on companies subject to payments and how funds are used, ensuring accountability for research spending.
  • Failure to pay has consequences: Drugs from companies that do not remit required payments may be deemed unlawful, potentially affecting their market availability.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Welch, Peter [D-VT-At Large].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health Public Investments